Filtered By:
Condition: Heart Valve Disease
Education: Study
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 330 results found since Jan 2013.
Personalizing Medicine: Considering Preferences and Values
If you're interested in heart disease -- and who over the age of 40 isn't? -- you may have read an excellent series of articles by reporter Gina Kolata recently published in the New York Times. If you haven't seen it, the series includes pieces on blood pressure, stents, heart attack treatment and a new approach to aortic valve replacement. The heart valve article especially caught my eye, as this is a story I've been watching with personal interest: My 90-year-old mother has aortic stenosis for which surgery has been recommended. In fact, surgery was first recommended for my mom at least six years ago. I know that timing ...
Source: Healthy Living - The Huffington Post - July 10, 2015 Category: Consumer Health News Source Type: news
Low Incidence of Paravalvular Leakage With the Balloon-Expandable Sapien 3 Transcatheter Heart Valve.
CONCLUSIONS: The present study shows excellent clinical and hemodynamic outcomes of high-risk transapical valve replacement patients treated with the new S3 THV. The S3 THV shows a low incidence of postoperative aortic regurgitation, with 98% presenting with less than mild aortic regurgitation.
PMID: 26117587 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - June 24, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Wendt D, Al-Rashid F, Kahlert P, Eißmann M, El-Chilali K, Janosi A, Pasa S, Tsagakis K, Liakopoulos O, Erbel R, Jakob H, Thielmann M Tags: Ann Thorac Surg Source Type: research
Low Incidence of Paravalvular Leakage With the Balloon-Expandable Sapien 3 Transcatheter Heart Valve
Conclusions The present study shows excellent clinical and hemodynamic outcomes of high-risk transapical valve replacement patients treated with the new S3 THV. The S3 THV shows a low incidence of postoperative aortic regurgitation, with 98% presenting with less than mild aortic regurgitation.
Source: The Annals of Thoracic Surgery - June 24, 2015 Category: Cardiovascular & Thoracic Surgery Source Type: research
UPDATE: FDA OKs new Sapien 3 valve from Edwards
UPDATED June 18, 2015, with details from Edwards and Leerink Partners.
The FDA said today that it approved Edwards Lifesciences‘s (NYSE:EW) Sapien 3 transcatheter heart valve for inoperable or high-risk patients with a narrowing in the heart’s aortic valve.
The approval was based on a 583-patient clinical study of patients who were at high risk for open heart surgery or who could not undergo the surgery due to excess risk, the federal watchdog said.
“Clinical data showed that the Sapien 3 transcatheter heart valve is superior to the 1st generation Sapien transcatheter heart valve, with significantly l...
Source: Mass Device - June 17, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Edwards Lifesciences Source Type: news
TAVI: Boston Scientific’s Lotus valve tops Medtronic’s CoreValve – study
Data from a study of Boston Scientific‘s (NYSE:BSX) Lotus Valve showed a greater device success rate than Medtronic‘s (NYSE:MDT) CoreValve in high-risk transcatheter aortic valve replacement patients.
The single-center, non-randomized study, published this month in the journal JACC: Cardiovascular Interventions, compared outcomes from 50 high-risk TAVI patients treated with the Lotus valve and 50 similar patients treated with Medtronic’s self-expanding CoreValve device.
Success rates were higher at 30 days in the Lotus group, at 84%, versus 64% with CoreValve, according to the study. These results...
Source: Mass Device - June 17, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Clinical Trials Replacement Heart Valves Boston Scientific JACC: Cardiovascular Interventions medtronic Source Type: news
TAVI: Good early data for Keystone Heart’s TriGuard
Data from a trial of Keystone Heart‘s TriGuard anti-stroke device showed a lower rate of neurologic deficits after transcatheter aortic valve implantation, according to research presented last month at EuroPCR 2015 in Paris. The 85-patient Deflect 3 study found that TAVI patients treated with the Israeli company’s TriGuard, which is designed to allow blood to […]
The post TAVI: Good early data for Keystone Heart’s TriGuard appeared first on MassDevice.
Source: Mass Device - June 2, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Neurological Replacement Heart Valves Keystone Heart TAVI Source Type: news
Lambl's Excrescences: Association with Cerebrovascular Disease and Pathogenesis
Conclusions: In this study, LEx are similarly prevalent in healthy controls and SLE patients, are not associated with CVD, and are not associated with pathogenic risk factors. Therefore, the study findings suggest that LEx may not be cardioembolic substrates, may not represent pathologic valve structures, and may not require therapy.Cerebrovasc Dis 2015;40:18-27
Source: Cerebrovascular Diseases - June 1, 2015 Category: Neurology Source Type: research
Transapical Transcatheter Aortic Valve Implantation Using the JenaValve: A One-Year Follow-up.
Conclusion The JenaValve transapical TAVI system is a safe and feasible procedure with low peri- and postoperative complications and convincing midterm performance of the prosthesis.
PMID: 26030120 [PubMed - as supplied by publisher]
Source: The Thoracic and Cardiovascular Surgeon - June 1, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Reuthebuch O, Koechlin L, Kaufmann BA, Kessel-Schaefer A, Gahl B, Eckstein FS Tags: Thorac Cardiovasc Surg Source Type: research
Transapical Transcatheter Aortic Valve Implantation Using the JenaValve: A One-Year Follow-up
Conclusion The JenaValve transapical TAVI system is a safe and feasible procedure with low peri- and postoperative complications and convincing midterm performance of the prosthesis.[...]Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals:Table of contents | Abstract | Full text
Source: The Thoracic and Cardiovascular Surgeon - June 1, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Reuthebuch, OliverKoechlin, LucaKaufmann, Beat A.Kessel-Schaefer, ArnheidGahl, BrigittaEckstein, Friedrich S. Tags: Original Cardiovascular Source Type: research
The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial
In conclusion, more frequent PST improved TTR and reduced the proportion of poorly managed patients.
Source: Journal of Thrombosis and Thrombolysis - May 29, 2015 Category: Hematology Source Type: research
What is the best approach in a patient with a failed aortic bioprosthetic valve: transcatheter aortic valve replacement or redo aortic valve replacement?
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether transcatheter aortic valve-in-valve replacement (viv-TAVR) or redo aortic valve replacement (rAVR) is the best strategy in a patient with a degenerative bioprosthetic aortic valve. Altogether, 162 papers were found using the reported search, of which 12 represented the best evidence to answer the question. The authors, journal, date, country of publication, patient group, study type, outcomes and results of papers are tabulated. The results of the studies provided interesting results. All the studies ...
Source: Interactive CardioVascular and Thoracic Surgery - May 28, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Tourmousoglou, C., Rao, V., Lalos, S., Dougenis, D. Tags: Lung - cancer, Trachea and bronchi, Congestive Heart Failure, Transplantation - heart, Valve disease, Vascular malformations Adult Cardiac Source Type: research
Thirty-day VARC-2 and performance data of a new self-expanding transcatheter aortic heart valve.
CONCLUSIONS: In this first-in-human study, the feasibility of implantation of the BIOVALVE system and its re-sheathing functionality was demonstrated, and short-term safety data were encouraging. Larger studies are required to confirm the performance of the device.
PMID: 25983028 [PubMed - as supplied by publisher]
Source: EuroIntervention - May 21, 2015 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
John Glenn Says Evolution Should Be Taught In Schools
COLUMBUS, Ohio (AP) — John Glenn, who declared as a 77-year-old in a news conference from space that "to look out at this kind of creation out here and not believe in God is to me impossible," says facts about scientific discovery should be taught in schools — and that includes evolution.
The astronaut, now 93 with fading eyesight and hearing, told The Associated Press in a recent interview that he sees no contradiction between believing in God and believing in evolution.
"I don't see that I'm any less religious by the fact that I can appreciate the fact that science just records that we change with evolution and tim...
Source: Science - The Huffington Post - May 20, 2015 Category: Science Source Type: news
Effect of aortic annulus size and prosthesis oversizing on the hemodynamics and leaflet bending stress of transcatheter valves: an in vitro study
Conclusions The hemodynamic performance of THV is, in large part, determined by the aortic annulus diameter in which the valve is deployed. Oversizing (up to 20% in area) has no significant effect on valve EOA but is associated with higher leaflet bending stress, which might promote faster structural valve degeneration in the long-term. Teaser Paravalvular regurgitation is still an important complication following transcatheter aortic valve implantation. The use modest prosthesis oversizing (i.e. 5-10%) was suggested to reduce their incidence. This study suggests that oversizing (up to 20 % in area) has no significant effe...
Source: Canadian Journal of Cardiology - April 21, 2015 Category: Cardiology Source Type: research
Knowledge Regarding Oral Anticoagulation Therapy among Patients with Stroke and Those at High Risk of Thromboembolic Events (P6.241)
Conclusion- Patient’s knowledge about OAT was suboptimal. The findings support the need for educational interventions to improve the knowledge regarding oral anticoagulation therapy, and thereby achieve an appropriate and safe secondary prevention of stroke.Disclosure: Dr. Bhatia has nothing to disclose. Dr. Alphonsa has nothing to disclose. Dr. Sharma has nothing to disclose. Dr. Sharma has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Bhatia, R., Alphonsa, A., Sharma, K., Sharma, G. Tags: Cerebrovascular Disease and Interventional Neurology: Thrombolysis Complications Source Type: research
